• FTC001(CNTO6785)is a highly potent human mAb directed against IL-17A. FTC001(CNTO6785) shows good pharmaceutical characteristics and clinical safety in pre-clinical and clinical studies
• We plan to license additional drug development programs into our pipeline at the late pre-clinical or early clinical stage and advance candidates to the market. Our team has expertise across multiple disease areas, mechanisms, and molecule types as well as CMC, project management and business development. Fontacea is teamed up with top experts from the world
• Our scalable business model and flexibility in cooperation ways make us an excellent partner for biotechnology and pharmaceutical companies seeking to scale up their development into China

To get more information on pipeline, please contact yanliangchu@fontacea.com

Better affordable medicines for patients in China and beyond.